1Zheng SS,Xu X,Wu J,et al.Liver transplantation for hepatoeellular carcinoma:Hangzhou experiences.Transplantation,2008,85:1726-1732.
2Mailey B,Artinyan A,Khalili J,et al.Evaluation of absolute serum α-fetoprotein levels in liver transplant for hepatocellular cancer.Arch Surg,2011,146:26-33.
3Sieghart W,Wang X,Schmid K,et al.Osteopontin expression predicts overall survival after liver transplantation for hepatocellular carcinoma in patients beyond the Milan criteria.J Hepatol,2011,54:89-97.
4Fumiaki Sato,Etsuro Hatano,Koji Kitamura,et al.MicroRNA Profile Predicts Recurrence after Resection in Patients with Hepatocellular Carcinoma within the Milan Criteria.PLoS One,2011,6:e16435.
5Zimmerman MA,TrotterJF,Wachs M,el al.Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma.Liver transplant,2008,14:633-638.
6Yeganeh M,Finn RS,Saab S.Apparent remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib.Am J Transplant,2009,9:2851-2854.
7Kim R,El-Gazzaz G,Tan A,et al.Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation.Oncology,2010,79:62-66.
8Valdivieso A,Bustamante J,Gastaca M,et al.Management of hepatocellular carcinoma recurrence after liver transplantation.Transplant Proc,2010,42:660-662.
7Kirk GD,Bah E,Montesano R.Molecular epidemiology of human liver cancer:insights into etiology,pathogenesis and prevention from the Gambia,West Africa.Carcinogenesis,2006,27:2070-2082.
8Mazzaferro V,Regalia E,Doci R,et al.Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.N Engl J Med,1996,334:693-699.
9Poon RT,Fan ST,Lo CM,et al.Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function:implications for a strategy of salvage transplantation.Ann Surg,2002,235:373-382.
10Llovet JM,Fuster J,Bruix J.Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma:resection versus transplantation.Hepatology,1999,30:1434-1440.
9Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in Advanced Hepatocellular Carcinoma. N Engl J Med, 2008,359: 378-390.
10Saab S, McTigue M, Finn RS, Busuttil RW, et al. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients : feasibility and efficacy. Exp Clin Transplant, 2010,8:307-313.
